Effect of Enpagliflozin on left ventricular function, blood glucose and lipid level in T2DM patients
10.3760/cma.j.cn121382-20210227-00405
- VernacularTitle:恩格列净对2型糖尿病患者左心功能及血糖血脂水平变化的影响分析
- Author:
Huixia JIA
1
;
Lei GAO
Author Information
1. 天津医科大学朱宪彝纪念医院超声科，天津市内分泌研究所，国家卫健委激素与发育重点实验室，天津市代谢性疾病重点实验室 300134
- Keywords:
Diabetes mellitus, type 2;
Empagliflozin;
Left ventricula diastolic function;
Blood glucose;
Blood lipid
- From:
International Journal of Biomedical Engineering
2021;44(4):281-285
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the effects of Empagliflozin on left ventricular function and the level of blood glucose and lipid in type 2 diabetes mellitus (T2DM) patients.Methods:A total of 120 patients with T2DM complicated with cardiac function impairment were selected from Chu Hsien-I Memorial Hospital, Tianjin Medical University from December 2020 to May 2021. The diabetic patients were randomly divided into the observation group (60 cases) and control group (60 cases) by random number table method. Patients in the observation group were treated with Empagliflozin, while the control group underwent original hypoglycemic treatment. After the treatment, 6 cases were eliminated and 114 cases were completed, with 57 cases in each group. The changes of echocardiographic left ventricular function related indexes such as E/ e', left atrial volume index (LAVI), tricuspid regurgitation speed, left ventricular ejection fraction (LVEF) and laboratory indexes in the two groups were observed before and after treatment. The laboratory indexes checked include fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL) and how density lipoprotein (HDL). Results:The E/ e', LAVI of the observation groups was significantly lower than that of the control group, and the differences were statistically significant (all P<0.05). There were no significant changes in tricuspid regurgitation speed, LVEF, TG, TC, LDL and HDL levels between the two groups after the treatment (all P>0.05). After the treatment, the levels of FBG and HbA1c in the two groups decreased, but there was no significant difference between the two groups (all P>0.05). Conclusions:Empagliflozin can effectively control the E/ e', LAVI of T2DM patients, and can early significant improvement of left ventricula diastolic function, which is very favorable for the patients. Along with good safety, Empagliflozin is suitable for clinical recommendation.
